Message from the President

Dear ACDS Member,

As we wrap up 2025, I want to thank all our members for your continued support of the ACDS from attending the conferences, to educating your patients and colleagues about patch testing, and providing valuable feedback so we can improve the society.
 

Some updates:

We held the ACDS Fall Meeting in person from October 16-18th in Charleston, SC. The meeting kicked off with a patch testing workshop that was open to new members, residents, and veteran members looking to reinforce their patch testing skills. The meeting included phenomenal speakers presenting a wide range of pertinent topics including Dr. Richard Vargo, an oral pathologist from St. Louis University speaking on oral contact allergies, to Dr. Mark Davis talking about hand/foot dermatitis and Dr. Golara Honari speaking about using AI in patch testing. We look forward to seeing you all at our next meeting, which will be the 37^th Annual Meeting held on Thursday before the AAD in Denver, CO, on March 26^th, 2026, at the Grand Hyatt Denver. As always, we will be hosting a Contact Allergen Bee so sign up your residents or fellows for a chance to win $1,000!
 

Last month, members of the ACDS were invited to participate in an FDA workshop where we discussed the regulatory environment of patch testing in the United States. The ACDS is actively engaged in conversation with the AAD and the FDA to support access to comprehensive patch testing and availability of a wide breadth of contact allergens for patients. The proceedings from the meeting will be published in the Dermatitis Journal in the future. Please stay tuned for further updates and information.
 

CAMP continues to provide value for our members, by providing allergen-free options for patients. App users can now purchase products through trusted Amazon links. In the coming months, be on the lookout for updated allergen handouts and our new diet handouts!
 

The ACDS will be involved in several international meetings in the coming years. We will be hosting several sessions at the upcoming European Society of Contact Dermatitis Society meeting in Copenhagen from June 24-27, 2026. We hope to see many members there! We will also have a half-day ACDS meeting held in conjunction with the World Congress of Dermatology in Guadalajara, Mexico on June 21 in 2027. More details to follow.
 

Finally, if you have not yet renewed for the upcoming year, we encourage you to renew your ACDS membership to maintain access to CAMP, the Dermatitis Journal, and our many other member benefits and resources.

If you have member news or information you would like highlighted in a future ACDS Newsletter, please email it to info@contactderm.org.

Sincerely,

JiaDe (Jeff) Yu, MD, MS
ACDS President

American Contact Dermatitis Society
555 E. Wells Street, Suite 1100 | Milwaukee, WI 53202
Phone: (414) 918-9805 | Fax: (414) 276-3349 | Email: info@contactderm.org
www.contactderm.org

Back to the Top

Now Accepting 2026 ACDS Membership Applications & Renewals

Renew in 5 Easy Steps

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Need an alternate renewal method?

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Expanded Payment Options

Credit Card* (American Express, Discover, MasterCard, and Visa)

*3% credit card processing fee will apply

E-Check** / ACH**
To utilize this payment option, a saved payment method is required. You can update or remove your saved payment methods anytime by logging in to the ACDS website and selecting My Payment Methods on the left navigation menu in your Personal Snapshot.

**$2.25 transaction fee will apply

Check
Checks can be made out to American Contact Dermatitis Society and mailed to

American Contact Dermatitis Society
555 E Wells St. Suite 1100
Milwaukee, WI 53202

Back to the Top

Select Your Future ACDS Leadership!

Voting Deadline: Friday, December 19, 2025, at 11:59pm CST

The 2025-2026 ACDS Board of Director Elections includes three Board of Director positions. All positions will become effective March 27, 2026, following the ACDS 37^th Annual Meeting in Denver, CO.

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Visit the website or click on the photos or names to
learn more about the following candidates.

Board of Directors

The three candidates with the majority of the votes will be appointed to the three open Board of Director positions. Each Director will serve for a three year term.

Sophia Colantonio, BSc, MPH, MD Ottawa, ON	Kelly Hoskins Tyler, MD Columbus, OH	Emily Milam, MD New York, NY
Megan Rogge, MD Bellaire, TX	Jamie Schlarbaum, MD Salt Lake City, UT	Peggy Wu, MD, MPH Sacramento, CA

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Voting Deadline: Friday, December 19, 2025,
at 11:59pm CST

Back to the Top

Online Registration Opening SOON!

We look forward to welcoming attendees to Denver, CO for the ACDS 37^th Annual Meeting, Thursday, March 26, 2026, to be held at the Grand Hyatt Denver.

Thank you for your patience as we work out the bugs in the 2026 online registration. Get ahead by completing the PDF registration form and sending it to info@contactderm.org.

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

ACDS 2026 Fisher Lecturer

We are pleased to announce Mark Denis P. Davis, MD, has been selected as the Alexander Fisher keynote speaker for the ACDS 37^th Annual Meeting. This award is the highest honor given by the society, and we look forward to Dr. Davis' presentation titled "Lessons Learned and Challenges Remaining in Patch Testing."

Mark Denis P. Davis, MD

Lessons Learned and Challenges Remaining in Patch Testing

Mark Denis P. Davis, M.D., is a consultant and serves as chair of the Department of Dermatology at Mayo Clinic in Rochester, Minnesota. Dr. Davis joined the staff of Mayo Clinic in 1997 and holds the academic rank of professor of dermatology, Mayo Clinic College of Medicine and Science.

Dr. Davis earned his medical degree (M.S., B.Ch.), from the Royal College of Surgeons of Ireland. His initial training included four years of internal medicine residency based at and coordinated by the hospitals of the Royal College of Physicians of Ireland. He then completed a residency in internal medicine followed by a residency in dermatology at the Department of Dermatology at Mayo Clinic, where he also served as chief resident. He subsequently earned his medical doctorate degree at the National University of Ireland.

Dr. Davis’ broad clinical and research interests include complex medical dermatology and hospital dermatology.  Another interest is the impact of climate change on dermatology. In recognition of his contributions to the specialty of dermatology, he received the 2022 Presidential Citation Award, conferred by the American Academy of Dermatology. 

He was the recipient of the Certificate of Appreciation in International Leadership awarded by the International League of Dermatological Societies in 2022, in recognition of outstanding and exemplary contributions to promoting and influencing dermatology at the national and international levels. 

Dr. Davis is frequently invited to give presentations on his research both nationally and internationally, and he has authored over 260 peer-reviewed journal articles, in addition to multiple abstracts and book chapters. He also edited and coordinated two books detailing the 100-year history of the Department of Dermatology at Mayo Clinic. He serves on the editorial boards of Mayo Clinic Health Letter and Mayo Clinic Proceedings, and he is leader of the Knowledge Content Board – Dermatology (Adult) for AskMayoExpert.

In addition to his clinical and research activities, Dr. Davis has mentored many residents and medical students. He has received awards for his excellence in teaching from Mayo Clinic School of Medicine (now known as Mayo Clinic Alix School of Medicine). He has also been recognized as Outstanding Faculty in Mayo Clinic School of Continuous Professional Development.

Dr. Davis is an active member of the American Academy of Dermatology, American Contact Dermatitis Society, European Academy of Dermatology and Venereology, International Society of Dermatology, and a founding member of the Rheumatologic Dermatology Society.

Back to the Top

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Register Today!

Thank you for your patience as we work out the bugs in the 2026 online registration. Get ahead by completing the PDF registration form and sending it to info@contactderm.org.

In-person registration is open for the ACDS 37^th Annual Meeting; we will not be offering a virtual component for this event.

Early Bird registration ends at 11:59pm CST on February 20, 2026. Registration after this date will result in the regular rate being applied.

Register HERE

Back to the Top

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Attention Residents:
16^th Annual Contact Allergen Bee

Come test your contact allergen knowledge by participating in the 16^th Annual CONTACT ALLERGEN BEE - a fun and engaging live trivia contest sponsored by the ACDS Dermatitis Journal! Winners are awarded up to $1,000 ($2,000 in total prizes)! Questions are multiple choice and based on papers published in Dermatitis from January, 2025 through December, 2025 and any past ACDS Allergen of the Year articles.

Dermatology residents or allergy and occupational medicine fellows in good standing, who are currently enrolled in an ACGME or international equivalent program are eligible.

In order to participate in the Contact Allergen Bee, your attendance is required at the pre-Bee meeting held onsite March 26^th in the afternoon. This meeting will cover rules, qualifications, and other necessary information.

Limited spots available - secure your spot early! Sign-up through the Annual Meeting registration or by emailing us or calling the ACDS office at (414) 918-9805.

Deadline to register for the Bee is Friday, February 20, 2026.

Back to the Top

2025 Fall Meeting Highlights

The 2025 Fall Meeting of the American Contact Dermatitis Society (ACDS) was held October 16^th-18^th in Charleston, South Carolina. The meeting featured outstanding speakers and engaging topics. The planning committee included Chair Dr. Nicole Burkemper and Deputy Chair Dr. Rabina Walsh, along with members Drs. Douglas Powell, JiaDe “Jeff “Yu, Margaret Hammond, Marjorie Montanez-Wiscovich, Rosemary DeShazo, and Sonja Molin.

On Thursday afternoon, we conducted a very successful Basics of Patch Testing Workshop. Dr. Burkemper, Dr. Deshazo, Dr. Walsh, and Dr. Wei-Che Ko participated in teaching residents, physician extenders and even some experienced physicians in the basics of contact dermatitis and starting a patch clinic.  Dormer Laboratories, Inc. / Chemotechnique Diagnostics sponsored the workshop and provided scholarships for attending residents, as well as samples of common patch testing supplies. The workshop included two live patients, recruited from local dermatologist and patch tester, Dr. Jennifer Steele, that allowed us to demonstrate in vivo how to remove and read patch tests. The patients were very generous with their time, allowing us to discuss their history and presentation of contact dermatitis.

On Friday morning, the meeting began with Dr. Jeff Yu, Associate Professor and Chair of Dermatology at Virginia Commonwealth University, speaking during the LEO Pharma, Inc.-sponsored morning session on the topic of chronic hand eczema. He was joined by a live patient who eloquently spoke about how chronic hand eczema has impacted her life. Program Chair, Dr. Nicole Burkemper, then gave the opening remarks and welcomed attendees to Charleston.

The meeting was organized into focused segments. Friday continued with Perspective: The Interplay of Other Specialties with Dermatitis, Debates in Dermatitis and Beyond the Skin - Extracutaneous Manifestations of Dermatitis. Dr. Burkemper moderated the first segment with Dr. Richard Vargo, a dentist and oral pathologist from SSM Health/Saint Louis University School of Medicine, Dr. Robert Lark, Professor of Orthopedic Surgery at Duke University School of Medicine and Dr. Katherine Lee, a faculty dermatologist with Health Partners/Park Nicollet.

Dr. Rabina Walsh then moderated our “Debates in Dermatitis” with Dr. M. Yadira Hurley, Professor and Chair of Dermatology at SSM Health/Saint Louis University speaking on the relationship of biologics with lymphoma, Dr. Margo Reeder, Associate Professor of Dermatology at University of Wisconsin, discussing food avoidance, Dr. Jenny Murase, Associate Clinical Professor at the University of California San Francisco, speaking on whether dupilumab treats allergic contact dermatitis and finally the gut and skin microbiome was presented by Dr. Zelma Chiesa Fuxench, Associate Professor of Dermatology at University of Pennsylvania.

Dr. Rosemary Deshazo moderated the Beyond the Skin - Extracutaneous Manifestations of Dermatitis section. Dr. Margo Reeder spoke on Sleep Disturbances in Patients with Dermatitis, Dr. Katlein Franca, Associate Professor of Dermatology at University of Miami Miller School of Medicine, discussed Mental Health Disorders in Patients with Dermatitis and Dr. Zachary Hopkins, Assistant Professor of Dermatology at University of Utah, presented on The Impact of Atopic Dermatitis on Social Functioning, Implications for Management.

After a few hours of free time to explore Charleston, we enjoyed an evening of socializing and merriment at Prohibition Charleston. The weather was perfect for our reserved space on the patio.

On Saturday morning, our meeting started with Dr. Priya Young, Dermatologist in Indianapolis, speaking during the Sanofi and Regeneron Pharmaceuticals, Inc.-sponsored session on Diagnosing and Assessing Prurigo Nodularis. Dr. Marjorie Montanez-Wiscovich moderated the first segment on Regional Dermatitis. Dr. Golara Honari, Clinical Associate Professor of Dermatology at Stanford Medicine, spoke on head and neck dermatitis, Dr. Melissa Mauskar, Associate Professor of Dermatology and OB/Gyn at University of Texas, Southwestern, was joined by her Chief Resident, Dr. Sydney Dixon to discuss anogenital dermatitis, and Dr. Mark Davis, Professor and Chair of Dermatology at Mayo Clinic Rochester, spoke about hand and foot dermatitis.

We continued the tradition of the always popular Ask the Experts Panel with Drs. Amber R. Atwater, Clinical Associate Professor of Dermatology at George Washington University, Mark Davis, Douglas Powell, Clinical Professor of Dermatology at the University of Utah, and Jeff Yu, Associate Professor and Chair of at Virginia Commonwealth University discussing Therapeutic Pearls in Unique Clinical Scenarios and “End of the Road” Patients as well as taking questions from the attendees. Dr. Burkemper moderated.

Our last session, moderated by Dr. Doug Powell focused on Patient Education Resources. Dr. Sara Hylwa,a faculty dermatologist with Health Partners/Park Nicollet, presented How Well Are We Educating?. Dr. Golara Honari spoke on Use of AI, Dr. Jamie Schlarbaum, Assistant Professor of Dermatology at University of Utah, discussed Allergen-Free Objects and finally Dr. Amber R. Atwater presented CAMP: A Year in Review.

The Fall Meeting was a great success due to the very hard work of Angela Logemann, ACDS Membership and Administrative Manager, and Ginger Czajkowski, ACDS Executive Director. Many thanks to them for their dedication to our organization. And thank you for attending this year’s meeting. We look forward to seeing everyone next year at the 37^th Annual Meeting, which will take place March 26, 2026, in Denver, CO.

Submitted by:
Nicole Burkemper, MD
2025 Fall Meeting Committee Chair

Back to the Top

Synopsis of US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) Public Workshop: Approval of New Patch Tests for the Diagnosis of Allergic Contact Dermatitis

Public/Virtual Conference | October 23, 2025

ACDS members actively participated in formal presentations and discussions at this FDA workshop last month. A detailed summary of each presentation and discussions will be forthcoming in Dermatitis. We provide an overview and synopsis.

The purpose of the workshop was 1) to provide information about and gain perspective from health care providers, academia and industry on approaches used for the review and approval of new patch test allergens to aid in the diagnosis of allergic contact dermatitis (ACD) and 2) to inform the Agency of the need for rapid approval of new patch test allergens, the utility of the Agency’s current approval paradigm and proposals for alternative approaches.

The workshop goals were to inform:

1. Stakeholders about the current regulatory status of patch tests to aid the diagnosis of ACD.
2. FDA regulators of up-to-date information about the diagnosis of ACD using patch testing.
3. Stakeholders of the requirements to license patch tests in the US and the EU.

FDA Workshop Morning Highlights: Epidemiology and Impact of ACD

David Kaslow MD, Director of the Office of Vaccines Research and Review at CBER welcomed participants and presented the above purpose and goals of the workshop. He also noted:

1. ACD affects a major portion of the population and our health care system; avoidance of allergens is key, and today’s licensed patch tests cover a little more than one third of recommended standard patch tests.
2. Patch tests are regulated as biologics, and must be licensed as safe, pure, potent and, although challenging, effective through well-controlled clinical investigations.
3. Patch test safety is overall good due to minimal absorption, and the path forward will require collaboration of all stakeholders.
4. FDA CBER’s mission is to protect and enhance public health and trust; and inflexibility may not serve patients best.

Superb detailed educational presentations followed: Epidemiology and Pathophysiology of ACD (Allison Ehrlich MD MHS); Occupational Contact Dermatitis (Karin Pacheco MD MSPH); Economic Burden of ACD (Jennifer Chen MD) and Contact Dermatitis in Children (JiaDe Yu MD MS). This was followed by several engaging patient experience video testimonials, demonstrating the importance and value of patch testing.

FDA Workshop Afternoon Highlights: Closing Gaps in Patch Testing

The afternoon sessions focused on advancing diagnostic strategies for ACD. Midday discussions included global perspectives, with Dr. Vera Mahler outlining regulatory considerations for patch test preparations in Europe and Dr. Joel DeKoven discussing the approach to allergen approval in Canada. Dr. Curt Hamann discussed insights on designing patch tests for optimal sensitivity and specificity. Dr. Amber Atwater reviewed patch test availability and shortages across regions, while Dr. Bruce Brod highlighted the critical role of comprehensive and supplemental testing to prevent missed diagnoses. Dr. Alexandra Flamm addressed persistent gaps such as limited access, personalization, and flexibility, while Dr. Luz Fonacier explored alternative diagnostic strategies when patch testing isn’t feasible.

Key Takeaways

• Access Gaps Persist: Regional shortages and limited allergen availability hinder care.
• Comprehensive Testing Is Essential: Supplemental panels prevent missed diagnoses and uninterrupted access to our current allergens is critical for patient care.
• Allergen Integrity Matters: Stability and manufacturing quality are essential for reliable results.
• Alternatives: Empiric avoidance and investigational methods were reviewed. Patch testing is still the gold standard.
• Patient Impact: Accurate patch testing dramatically improves quality of life and allows for the ability to work.

Submitted by:
Bruce A. Brod, MD, FAAD
Alex Flamm, MD, FAAD
James S. Taylor, MD, FAAD

Back to the Top

Retirement of Dr. Lisa Garner

Lisa A. Garner was a board-certified dermatologist with close to 40 years of experience practicing in Garland, Texas and Belleair, Florida. She earned her MD degree from Baylor College of Medicine and completed her residency in Dermatology at University of Texas Southwestern Medical School, where she served as chief resident.

She was a clinical professor of Dermatology at UTSW, and held numerous leadership positions in professional societies, including Board of Directors and as Vice President of the AAD from 2008-12 and 2013-14, respectively. She served as president of the national Women’s Dermatologic Society.  She was honored by the Dermatology Foundation as the 2017 Practitioner of the Year for her service as a practitioner and teacher.

She served as an Associate Editor and then as a Section Editor for Dermatitis since 1999, when Ponciano “Chito” Cruz became Editor-in-Chief of the journal. With her recently announced retirement from clinical practice, she announced that she is stepping away from the Editorial Board of DERMATITIS.  

Lisa, congratulations for a very successful career in Dermatology, and for your many years of outstanding service to DERMATITIS and ACDS!  We are grateful to you for your role in the growth of  DERMATITIS.
 

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Practical Techniques in Dermatology

In our Sept/Oct issue of DERMATITIS, we published a notable manuscript under the category of Practical Techniques in Dermatology: “Updates to the Research Institute for Fragrance Materials, Inc. Confirmation of No Induction in Human Test Standard Protocol”, with Anne Marie Api, PhD as the senior author. This manuscript addressed advances in the protocol to identify sensitization potential of fragrance materials in pre-clinical testing of human volunteers.

DERMATITIS continues to seek manuscripts that will provide practical techniques about procedures used to evaluate or manage cutaneous allergy including contact dermatitis, type I allergic reactions, reactions to environmental agents or systemic reactions to medications.   Examples may include, but are not limited to: novel methods for open or closed patch testing, scoring systems, clinical research methods, repeat open application tests, repeat insult patch tests, allergy alert tests, intradermal challenges, oral challenges, ocular challenges, extemporaneous formulations of patient-supplied materials for patch testing (such as personal care products, work-related products, materials derived from plants clothing, gloves, or other ‘non-standard’ allergens),  skin prick testing, photo-patch testing, photo-testing, opportunities to increase the efficiency of patch testing, and novel patient counseling materials. As appropriate, the articles may include commercial sources of materials needed to perform the techniques discussed, provided any author(s) conflicts of interest are disclosed.

Manuscripts can be up to 3000 words in length, include up to three figures or tables (additional supplemental on-line only figures, tables and videos are permitted).
 

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Coming in 2026

Toxin of the Year

In 2022, DERMATITIS added a fifth “Domain” of interest for the readership of our journal.  That is, Environmental Dermatitis.  With the assistance of a task force and newly recruited associate editors, we defined the scope of this Domain.  Briefly, the scope of the Environmental Dermatitis Domain is defined by allergic (both delayed and immediate) and irritant skin reactions to aeroallergens (house dust mite, molds, pollen, plants animal and insect dander), foods and protein contact dermatitis. It also includes dermatitis resulting from compromised skin barrier function.  It includes immediate and delayed skin tests to confirm these diagnoses caused numerous triggers. This includes prick, patch (including atopy patch tests and pollution patch tests) and intradermal tests as well as blood tests to diagnose such reactions. Main areas covered include basic biological mechanisms, diagnostic methods, experimental investigations and clinical aspects, including therapy. 

Importantly, the role of exposomal factors (whether indoors or outdoors) in inducing or modifying the course of such dermatitis is of interest.  This includes dust, smoke, pollutants, microbes, chemicals, ultraviolet radiation,  climatic and nutritional factors. It also includes reactions to dermatitis induced by bites, stings and evenomations from insects, reptiles and animals.

Our Associate Editor, Dr. Jean Krutmann and his team have written a ‘State of the Art’ review on the Toxin of the Year as a new feature of the journal to support the Environmental Dermatitis initiative. This feature has been modeled after the popular, long-standing feature of the journal “Allergen of the Year”.    The Toxin of the Year will be unveiled in one of the early issues in 2026. 
 

FDA Public Workshop on Approval of New Patch Tests for the Diagnosis of Allergic Contact Dermatitis

On October 23, 2025 the Food and Drug Administration (FDA) Office of Vaccines Research and Review hosted a full-day, virtual public workshop related to the approval of new patch tests for the diagnosis of allergic contact dermatitis. Members of the FDA, the ACDS, American Association of Asthma Allergy and Immunology (AAAAI), as well as Canadian and European Dermatologists presented information about patch testing and how patch tests are approved by regulatory agencies.  The participants of this workshop have agreed to work collaboratively to author a single “Whitepaper” related to the proceedings of this important meeting.   Some time in late 2026, Dermatitis will publish this whitepaper in our journal, so those of the ACDS who were not able to attend this important workshop will have the benefit of a summary of the proceedings, and thus learn about the administrative processes involved in patch test approval by regulatory bodies in the USA and abroad.
 

Submitted by:
Anthony Gaspari, MD
Dermatitis Editor-in-Chief

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Published by Mary Ann Liebert, Inc. and led by Anthony Gaspari, MD, Dermatitis^® is the leading peer-reviewed scientific journal in contact dermatitis, and the only journal in its field that publishes leading research in atopic, contact, occupational, environmental, and drug dermatitis.

The journal is an essential resource for dermatologists, allergists, immunologists, and toxicologists and is now available only from Mary Ann Liebert, Inc. - make sure you and your colleagues don't miss an issue!
 

Click here to request access from your institutional library now.

Back to the Top

Save the Date:

Hand Eczema Core Outcome Set (HECOS) Consensus Meeting

June 23 - 24, 2026, Copenhagen, Denmark

Dear Colleagues,

Please save the date for the upcoming HECOS consensus meeting June 23 (afternoon) - 24 (morning) 2026, in Copenhagen, Denmark, adjacent to ESCD congress.

At last year's international consensus meeting in Dresden, participants agreed on a set of core domains and subdomains that should be measured in all future therapeutic hand eczema trials. To produce comparable and meaningful results, such trials evaluating should measure 15 specific core subdomains including signs and symptoms of HE, HE-related quality of life, and HE control over time (in addition to study-specific outcomes). The HECOS initiative is currently conducting systematic reviews to identify appropriate measurement instruments.

We invite you, and your patients with hand eczema, to take part in the decision process.

Please note that registration is not yet open and the venue is not yet confirmed. The HECOS steering group will provide meeting details in late 2025.

Learn more about HECOS by visiting https://c3outcomes.com/hecos and reading Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of life.

Submitted by:
Dipl.-Soz. Henriette Rönsch
Wissenschaftliche Mitarbeiterin
Klinik und Poliklinik für Dermatologie

Back to the Top

The American Contact Dermatitis Society is committed to advancing the care and understanding of dermatology and allergy through the promotion of education, research and advocacy. As part of this initiative, ACDS offers the following educational awards to help encourage research in these areas:

Clinical Research Award

The American Contact Dermatitis Society offers awards for the purpose of relevant clinical studies directed toward the subject of contact dermatitis. Studies that focus on clinical problems or have applications to clinical problems will receive preferential consideration.

Click here to see a list of past Clinical Research Award recipients.

Mentoring Award

ACDS Mentoring Awards are granted for the purpose of assisting young dermatologists including dermatology residents, dermatology fellows, or dermatologist up to 5 years out of residency to become leaders/experts in the field of contact dermatitis by acquiring additional academic skills which may not be available at their training institutions.

Click here to see a list of past Mentoring Award recipients.

Mid-Career Award

The ACDS Mid-Career Development Award provides financial support for ACDS members to defray the cost of acquiring specific skills and knowledge to enhance their professional development in some aspect of contact dermatitis and/or occupational dermatology.

Click here to see a list of past Mid-Career Award recipients.

For more information on any of these opportunities,
please visit our website here.

Back to the Top

ACDS 2026 Mentoring Award

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

ACDS 2026 Clinical Research Award

· · · · · · · · · · · · • ♦ • · · · · · · · · · · · ·

Congratulations to all of these latest ACDS award recipients!

Back to the Top

Back to the Top

American Contact Dermatitis Society^®
555 East Wells Street, Suite 1100 | Milwaukee, WI 53202
P: (414) 918-9805 | F: (414) 276-3349 | info@contactderm.org

Follow ACDS^®

If you do not wish to be included in our mailing list, please forward this message to info@contactderm.org.